However, cytoplasmic evaluation has an uncertain biological relevance in CRC as well as in breast and gastric cancers, with no recognized role in standard scoring methodologies because of a possible overestimation of true HER2 positivity [91]. The gene discussed is ERBB2; the disease is gastric cancer.